Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Survival Curves

Survival Curves

Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Introduction To Survival Analysis

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multifunctional inverse opal scaffold loaded with FGF2 for tendon regeneration.

International journal of pharmaceutics·2026

Same author

Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial.

Ophthalmology. Retina·2026

Same author

Barriers to Adherence to Remote Pelvic Floor Muscle Training Among Postpartum Women: A Qualitative Study Guided by the COM-B Model.

Patient preference and adherence·2026

Same author

Comprehensive overview of triclosan neurotoxicity and construction of adverse outcome pathways using a systems toxicology approach: Triclosan-induced attention-deficit hyperactivity disorder as an example.

Ecotoxicology and environmental safety·2026

Same author

Editor's Note: Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Effects of different early intervention strategies guided by GMOS, PDMS-2, or their combination on motor outcomes in preterm infants with PIVH: a randomized trial.

European journal of medical research·2026

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Covariate-adjusted non-parametric survival curve estimation.

Honghua Jiang¹, James Symanowski, Yongming Qu

¹Eli Lilly and Company, US Commercial Information Sciences, IN 46285, USA. jianghh@lilly.com

Statistics in Medicine

|February 24, 2011

Summary

This study introduces a new non-parametric method for estimating covariate-adjusted survival curves, improving upon traditional Kaplan-Meier and Cox models. The novel approach enhances precision and reduces bias in clinical trial survival analysis.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Biostatistics
Clinical Trials
Survival Analysis

Background:

Kaplan-Meier curves are standard non-parametric tools for survival analysis but lack covariate adjustment.
Cox proportional hazards models offer covariate adjustment but rely on the often-unmet proportional hazards assumption.
Existing non-parametric methods for covariate-adjusted survival rates are limited to specific time intervals.

Purpose of the Study:

To develop a novel non-parametric method for estimating covariate-adjusted survival rates at any time point.
To extend existing non-parametric approaches to allow for covariate adjustment in survival analysis.
To provide a more flexible and robust alternative to existing survival curve estimation methods in clinical trials.

Main Methods:

Extension of a non-parametric covariate-adjusted method for survival rate estimation.
Development of a new model to estimate survival rates for treatment groups at any time point.
Conducting simulation studies to evaluate the performance of the proposed model.

Main Results:

The new model successfully estimates covariate-adjusted survival rates at any time point.
Simulation studies demonstrate the model's performance in various scenarios.
The method is illustrated using an oncology clinical trial, showing its practical applicability.

Conclusions:

The developed non-parametric model provides accurate covariate-adjusted survival rate estimations.
This method offers an improvement over traditional Kaplan-Meier and Cox models by allowing covariate adjustment without the proportional hazards assumption.
The approach is valuable for analyzing survival data in clinical trials, particularly in oncology.